Lipozate (Bezafibrate) (Bezafibrate)

• Bezafibrate is used to manage disorders of lipid metabolism, particularly conditions characterized by elevated cholesterol or triglyceride levels.
• Hyperlipidemia: reduces total cholesterol and LDL‑cholesterol, helping to meet guideline targets for cardiovascular risk reduction.
• Hypertriglyceridemia: lowers serum triglyceride concentrations, decreasing risk of pancreatitis associated with severe hypertriglyceridemia.
• Mixed dyslipidemia: improves overall lipid profile by decreasing triglycerides, lowering LDL‑cholesterol, and modestly raising HDL‑cholesterol.

• Bezafibrate activates the nuclear receptor peroxisome proliferator‑activated receptor alpha (PPARα). Activation enhances transcription of genes involved in fatty‑acid β‑oxidation, increases lipoprotein lipase activity, and suppresses hepatic synthesis of triglyceride‑rich very‑low‑density lipoproteins. The combined effect accelerates clearance of triglyceride‑rich particles and raises high‑density lipoprotein levels, resulting in improved plasma lipid concentrations. These molecular actions translate into reductions in plasma triglycerides and low‑density lipoprotein cholesterol while modestly increasing high‑density lipoprotein cholesterol.

Bezafibrate may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.
• Headache: mild to moderate intensity.
• Dizziness: transient episodes.
• Elevated liver enzymes: mild, reversible changes.

Serious or Rare Side Effects

• Myopathy or rhabdomyolysis: muscle pain with elevated creatine kinase.
• Severe hepatic dysfunction: jaundice or marked transaminase rise.
• Blood dyscrasias: thrombocytopenia, leukopenia or anemia.
• Life‑threatening skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Bezafibrate therapy, clinicians should evaluate several safety parameters and follow specific precautionary measures.

• Liver function monitoring: obtain baseline enzymes and repeat periodically.
• Renal function assessment: adjust use in patients with significant impairment.
• Creatine kinase evaluation: check if muscle symptoms develop.
• Concomitant statin use: avoid high‑dose statins to reduce myopathy risk.
• Store at ambient temperature: keep tablets in original packaging, protect from moisture and heat.

Bezafibrate can alter the pharmacokinetics or pharmacodynamics of several medicines; awareness of key interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Gemfibrozil: combined use markedly increases risk of myopathy.
• High‑dose statins (e.g., atorvastatin >40 mg): synergistic myopathy potential.
• Cyclosporine: may raise bezafibrate plasma concentrations.

Moderate Interactions (Monitor Closely)

• Oral hypoglycemic agents: bezafibrate can enhance glucose‑lowering effect.
• Thyroid hormone replacement: may require dose adjustment.
• Bile acid sequestrants (e.g., cholestyramine): can reduce bezafibrate absorption.